BIG against breast cancer

Last week, the San Antonio Breast Cancer Symposium conference brought together experts from around the world in San Antonio to discuss the latest advancements in #breastcancer #research! Our team members, Virginie Sarah Adam - Scientific Director at BIG, and Carmela Caballero - Senior Medical Advisor at BIG, were there, soaking in valuable insights to shape the future of breast cancer treatment. 💡 Some BIG updates were shared at the event, including on: #OLYMPIA: New results from the OlympiA trial show one year of treatment with the targeted drug olaparib improves long-term survival in women with high-risk, early-stage breast cancer with mutations in BRCA1 or BRCA2 genes. 10 years after the first patient was included we see that adding olaparib to standard treatment in early-stage inherited breast cancer cuts the risk of women dying by 28% and the risk of coming back by 35%.87.5% of patients who were treated with the drug were still alive compared with 83.2% of those who were given the placebo pills. #SUPREMO: The primary analysis of the SUPREMO trial indicates with high precision that radiation of the chest area following breast removal surgery in patients with 1-3 positive nodes or node-negative with other risk factors with modern multidisciplinary management has no impact on length of life after diagnosis and doesn't make a meaningful difference in the chance of cancer returning to the chest area. #MINDACT: When researchers looked closely at HER2-low breast cancers, they found these cancers aren't all the same. They vary in their genetic makeup, their risk levels, and how they respond to treatment. These results may influence future clinical trials with new agents for treatment for HER2 low early breast cancer. #DECRESCENDO: Great results were found in this exploratory analysis when treating early-stage breast cancer before surgery using a combination of drugs that didn't include anthracyclines (a type of chemotherapy drug that can affect the heart). The treatment worked very well for patients whose breast cancer with HER2-positive, HR-negative, node-negative who showed a complete response. Elisa Agostinetto Gustavo Werutsky Tanja Spanic Matteo Lambertini Judy Garber #BIGagainstbc #research #EU4Health European Health and Digital Executive Agency (HaDEA)

In a recent article from La Libre, Kris and Dina share their experience with breast cancer, a challenge that not only brought them closer together but also inspired them to advocate for BIG's cancer research. Kris, a survivor since 2010, and Dina, recently diagnosed, have joined forces to champion BIG's mission to advance treatments and improve outcomes for patients worldwide. Their powerful message: cherish every moment, even in the face of illness. 🙏 At BIG, stories like Kris and Dina’s fuel our resolve to drive impactful research and deliver hope to countless patients worldwide. Together, we’re making strides in the fight against breast cancer. Read the full article here 👉 https://shorturl.at/rynt4 #BIGagainstbc #BreastCancer #Research #EU4Health European Health and Digital Executive Agency (HaDEA)

Also this year I can confirm that San Antonio Breast Cancer Symposium is my fav congress of the year💕 I am so proud to have received an #EarlyInvestigatorAward for the study we presented today, and to share this achievement with the entire team of wonderful colleagues and friends! #SABCS24 OncoAlert Luca Arecco Carmela Caballero Virginie Sarah Adam Evandro de Azambuja Gabriele Zoppoli BIG against breast cancer Institut Jules Bordet

🏆 Support Hilde Dosogne for Belgian of the Year! 🏆 This year, Hilde Dosogne has embarked on an extraordinary journey: completing 366 marathons in 366 days. Since January 1, 2024, Hilde has run a marathon every single day—a feat of unmatched determination! Her mission goes beyond personal achievement. Hilde has raised over 32.000€ for BIG's #breastcancer #research, inspiring us all with her dedication, grit, and compassion. Earlier this year, she broke the Guinness World Record for the most consecutive marathons run by a woman (to be ratified by GWR). Now, Hilde has been nominated for Belgian of the Year by Het Laatste Nieuws and VTM Nieuws. It’s our chance to show our support. Let's recognise her incredible efforts and impact by casting your vote here: 👉 https://shorturl.at/ACnhq 💡 Every vote matters. Share this with your network to help Hilde cross this final finish line! #MoveforBIG #BIGagainstbc #EU4Health European Health and Digital Executive Agency (HaDEA)

✍️ We are pleased to announce the official signing of the European Project « Path4Young »! 🔬 On October 19th, BIG, with Unicancer, University of Warwick, Gustave Roussy, and 22 additional partners, signed a Grant Agreement for an ambitious new European project called Path4Young, led by Dr Ines Vaz-Luis from Gustave Roussy. The goal is to improve care for young women with hormone receptor-positive breast cancer (HR+). This European Union-funded project, based on an ongoing international multicenter clinical trial OPTIMA (@OPTIMAbstudy), seeks to redefine the care standards for premenopausal women considered at high risk of recurrence. 💡 This project represents a major step forward in tailoring breast cancer treatment for young women and providing innovative solutions to better support patients. Learn more about #Path4Young and our mission to reshape breast cancer care on our website: https://lnkd.in/eYpT_ADr 🌐 Unicancer, Gustave Roussy, Università degli Studi di Torino, Institut Jules Bordet, EUPATI, University of Warwick, Resilience, HeCOG, Cancer Trials Ireland Austrian Breast & Colorectal Cancer Study Group (ABCSG), GEICAM - Spanish Breast Cancer Group, GAICO, GECOPERU, LACOG - Latin American Cooperative Oncology Group, GOIRC, EUROPA DONNA - The European Breast Cancer Coalition, Instituto D'Or de Pesquisa e Ensino, AP-HP, Assistance Publique - Hôpitaux de Paris, IH, SOLTI, CEEOG, Dana-Farber Cancer Institute, Universidad de Castilla-La Mancha, Clinical Research Technology, Klineo #BreastCancer #Research #BIGagainstBC #HorizonEU European Commission European Health and Digital Executive Agency (HaDEA) #HaDEA

We'd like to express our heartfelt thanks to the European Commission and the European Health and Digital Executive Agency (HaDEA) for the invaluable support that #EU4Health co-funding is providing us this year. From our Pink October campaign to a special event with Her Majesty the Queen of the Belgians, and a gala evening to celebrate BIG's 25th anniversary, each of these meaningful activities was greatly enhanced by EU co-funding and the support we received from the European Commission and HaDEA. For the second consecutive year, the Breast International Group (BIG) has been awarded an operating grant under the EU4Health programme. This funding is crucial to support the activities of our organisation, which facilitate academic research for breast cancer. #BIG25years #BIGagainstbc #breastcancer #research

Our work describing HER2-positive breast cancer heterogeneity (from my PhD with Christos Sotiriou at Institut Jules Bordet) is out in Nature communications. ➡️We identified 5 molecular subtypes 🧬 in the ALTTO clinical trial (BIG against breast cancer) with external validations. ➡️We captured both tumor-intrinsic and microenvironment features. ➡️The subtypes showed prognostic value and, in neoadjuvant cohorts, differences in pCR rates. Grateful to Christos Sotiriou for his guidance, the team at the BCTL, and all co-Authors.

We are thrilled to announce that clinical and molecular data from the #LORELEI study are now accessible on the Vivli platform! 🔗 https://shorturl.at/YQMw4 The LORELEI study is a pivotal phase II, international, randomized, double-blind trial focused on ER-positive/HER2-negative early-stage breast cancer in postmenopausal women. By comparing letrozole plus taselisib (GDC-0032) with letrozole plus placebo, the study sought to uncover critical insights into treatment resistance and sensitivity in breast cancer therapy. Researchers can now delve into this rich dataset to advance understanding and spark new innovations in breast cancer care. 👏 A huge thank you to the LORELEI study team for enabling this milestone and empowering the research community with these insights. Austrian Breast & Colorectal Cancer Study Group (ABCSG), SOLTI #cancerresearch #Breastcancer #Research #BIG25years #EU4Health European Health and Digital Executive Agency (HaDEA)

Servaas Michielssens, PhD, CFA, our Head of Healthcare at Candriam, had the honour of participating in a meaningful roundtable discussion organized by BIG against breast cancer, attended by Her Majesty Queen Mathilde of Belgium. The event, which took place at TheMerode in Brussels, was a unique gathering of scientists, patient advocates, business leaders, and dedicated supporters, highlighting the latest advancements in breast cancer research and the impact of BIG's 25 years of dedication. Servaas engaged in insightful conversations about the urgent need for continued support of breast cancer research, emphasizing the importance of partnerships that can drive progress and improve the lives of patients worldwide. Our heartfelt thanks to Her Majesty Queen Mathilde for her commitment to this vital cause and to BIG for creating a space for such impactful discussions. Together, we can continue to make strides in the fight against breast cancer. 💖🎗️ #Investing4Tomorrow #BIGagainstbc #Healthcare #CancerResearch #SustainableInvesting #EU4Health

Thanks Philippe together with the coPIs Matteo Benelli and Angel Guerrero-Zotano , and all BIG against breast cancer colleagues for this huge, inspiring effort! Proud to be onboard 😊😊😊